We are analyzing https://link.springer.com/article/10.1007/s11095-006-9180-5.

Title:
Lipid-based Nanoparticles for Nucleic Acid Delivery | Pharmaceutical Research
Description:
Lipid-based colloidal particles have been extensively studied as systemic gene delivery carriers. The topic that we would like to emphasize is the formulation/assembly of lipid-based nanoparticles (NP) with diameter under 100 nm for delivering nucleic acid in vivo. NP are different from cationic lipid–nucleic acid complexes (lipoplexes) and are vesicles composed of lipids and encapsulated nucleic acids with a diameter less than 100 nm. The diameter of the NP is an important attribute to enable NP to overcome the various in vivo barriers for systemic gene delivery such as: the blood components, reticuloendothelial system (RES) uptake, tumor access, extracellular matrix components, and intracellular barriers. The major formulation factors that impact the diameter and encapsulation efficiency of DNA-containing NP include the lipid composition, nucleic acid to lipid ratio and formulation method. The particle assembly step is a critical one to make NP suitable for in vivo gene delivery. NP are often prepared using a dialysis method either from an aqueous-detergent or aqueous-organic solvent mixture. The resulting particles have diameters about 100 nm and nucleic acid encapsulation ratios are >80%. Additional components can then be added to the particle after it is formed. This ordered assembly strategy enables one to optimize the particle physico-chemical attributes to devise a biocompatible particle with increased gene transfer efficacy in vivo. The components included in the sequentially assembled NP include: poly(ethylene glycol) (PEG)-shielding to improve the particle pharmacokinetic behavior, a targeting ligand to facilitate the particle–cell recognition and in some case a bioresponsive lipid or pH-triggered polymer to enhance nucleic acid release and intracellular trafficking. A number of groups have observed that a PEG-shielded NP is a robust and modestly effective system for systemic gene or small interfering RNA (siRNA) delivery.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Shopping

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We see no obvious way the site makes money.

While profit motivates many websites, others exist to inspire, entertain, or provide valuable resources. Websites have a variety of goals. And this might be one of them. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

google, scholar, article, cas, pubmed, gene, delivery, dna, szoka, nucleic, ther, acid, particles, biophys, liposomes, cationic, huang, maclachlan, chem, cullis, stabilized, nanoparticles, systemic, res, therapy, vivo, lipid, assembly, drug, liposome, plasmidlipid, lee, complexes, sci, expression, encapsulation, transfer, zhang, rev, plasmid, scherrer, biochim, acta, molec, cells, privacy, cookies, content, research, components,

Topics {✒️}

lipid–protamine–dna-mediated antigen delivery nucleic acid–lipid nanoparticles lipid-mediated dna-transfection procedure month download article/chapter low-ph-sensitive poly small interfering rna nucleic acid-based therapeutics rnai-mediated gene silencing lipid-based nanoparticles stabilized plasmid–lipid particles antigen-presenting cells results dna–cationic liposome complexes cationic liposome/dna complexes serum-resistant gene delivery size-dependent dna mobility chapter google scholar lipoplex-mediated gene delivery nucleic acid delivery article google scholar particle physico-chemical attributes aqueous-organic solvent mixture vivo anti-hbv activity monomolecular dna nanoparticles delivering nucleic acid controlled template-assisted assembly ethanol-destabilized cationic liposomes protamine-condensed dna lipid–protamine–dna lipid–dna particles ph-triggered polymer ph-triggered collapse particle–cell recognition privacy choices/manage cookies full article pdf receptor-specific delivery encapsulated nucleic acids nucleic acids released related subjects enhanced gene delivery lipid-coated polyplexes stabilized plasmid nanlipoparticles folate-mediated delivery regional gene therapy targeted gene delivery systemic gene therapy anionic micelle environment bioresponsive gene carriers nucleic acid shape-specific nanobiomaterials targeted gene transfer

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Lipid-based Nanoparticles for Nucleic Acid Delivery
         description:Lipid-based colloidal particles have been extensively studied as systemic gene delivery carriers. The topic that we would like to emphasize is the formulation/assembly of lipid-based nanoparticles (NP) with diameter under 100 nm for delivering nucleic acid in vivo. NP are different from cationic lipid–nucleic acid complexes (lipoplexes) and are vesicles composed of lipids and encapsulated nucleic acids with a diameter less than 100 nm. The diameter of the NP is an important attribute to enable NP to overcome the various in vivo barriers for systemic gene delivery such as: the blood components, reticuloendothelial system (RES) uptake, tumor access, extracellular matrix components, and intracellular barriers. The major formulation factors that impact the diameter and encapsulation efficiency of DNA-containing NP include the lipid composition, nucleic acid to lipid ratio and formulation method. The particle assembly step is a critical one to make NP suitable for in vivo gene delivery. NP are often prepared using a dialysis method either from an aqueous-detergent or aqueous-organic solvent mixture. The resulting particles have diameters about 100 nm and nucleic acid encapsulation ratios are >80%. Additional components can then be added to the particle after it is formed. This ordered assembly strategy enables one to optimize the particle physico-chemical attributes to devise a biocompatible particle with increased gene transfer efficacy in vivo. The components included in the sequentially assembled NP include: poly(ethylene glycol) (PEG)-shielding to improve the particle pharmacokinetic behavior, a targeting ligand to facilitate the particle–cell recognition and in some case a bioresponsive lipid or pH-triggered polymer to enhance nucleic acid release and intracellular trafficking. A number of groups have observed that a PEG-shielded NP is a robust and modestly effective system for systemic gene or small interfering RNA (siRNA) delivery.
         datePublished:2007-01-25T00:00:00Z
         dateModified:2007-01-25T00:00:00Z
         pageStart:438
         pageEnd:449
         sameAs:https://doi.org/10.1007/s11095-006-9180-5
         keywords:
            DNA
            gene therapy
            liposome
            oligonucleotide
            small interfering RNA
            Pharmacology/Toxicology
            Pharmacy
            Biochemistry
            general
            Medical Law
            Biomedical Engineering and Bioengineering
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11095-006-9180-5/MediaObjects/11095_2006_9180_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11095-006-9180-5/MediaObjects/11095_2006_9180_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11095-006-9180-5/MediaObjects/11095_2006_9180_Fig3_HTML.gif
         isPartOf:
            name:Pharmaceutical Research
            issn:
               1573-904X
               0724-8741
            volumeNumber:24
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Weijun Li
               affiliation:
                     name:University of California at San Francisco
                     address:
                        name:Departments of Biopharmaceutical Sciences and Pharmaceutical Chemistry, School of Pharmacy, University of California at San Francisco, San Francisco, USA
                        type:PostalAddress
                     type:Organization
                     name:Bayer Pharmaceuticals Corporation
                     address:
                        name:Bayer Pharmaceuticals Corporation, Berkeley, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Francis C. Szoka
               affiliation:
                     name:University of California at San Francisco
                     address:
                        name:Departments of Biopharmaceutical Sciences and Pharmaceutical Chemistry, School of Pharmacy, University of California at San Francisco, San Francisco, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Lipid-based Nanoparticles for Nucleic Acid Delivery
      description:Lipid-based colloidal particles have been extensively studied as systemic gene delivery carriers. The topic that we would like to emphasize is the formulation/assembly of lipid-based nanoparticles (NP) with diameter under 100 nm for delivering nucleic acid in vivo. NP are different from cationic lipid–nucleic acid complexes (lipoplexes) and are vesicles composed of lipids and encapsulated nucleic acids with a diameter less than 100 nm. The diameter of the NP is an important attribute to enable NP to overcome the various in vivo barriers for systemic gene delivery such as: the blood components, reticuloendothelial system (RES) uptake, tumor access, extracellular matrix components, and intracellular barriers. The major formulation factors that impact the diameter and encapsulation efficiency of DNA-containing NP include the lipid composition, nucleic acid to lipid ratio and formulation method. The particle assembly step is a critical one to make NP suitable for in vivo gene delivery. NP are often prepared using a dialysis method either from an aqueous-detergent or aqueous-organic solvent mixture. The resulting particles have diameters about 100 nm and nucleic acid encapsulation ratios are >80%. Additional components can then be added to the particle after it is formed. This ordered assembly strategy enables one to optimize the particle physico-chemical attributes to devise a biocompatible particle with increased gene transfer efficacy in vivo. The components included in the sequentially assembled NP include: poly(ethylene glycol) (PEG)-shielding to improve the particle pharmacokinetic behavior, a targeting ligand to facilitate the particle–cell recognition and in some case a bioresponsive lipid or pH-triggered polymer to enhance nucleic acid release and intracellular trafficking. A number of groups have observed that a PEG-shielded NP is a robust and modestly effective system for systemic gene or small interfering RNA (siRNA) delivery.
      datePublished:2007-01-25T00:00:00Z
      dateModified:2007-01-25T00:00:00Z
      pageStart:438
      pageEnd:449
      sameAs:https://doi.org/10.1007/s11095-006-9180-5
      keywords:
         DNA
         gene therapy
         liposome
         oligonucleotide
         small interfering RNA
         Pharmacology/Toxicology
         Pharmacy
         Biochemistry
         general
         Medical Law
         Biomedical Engineering and Bioengineering
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11095-006-9180-5/MediaObjects/11095_2006_9180_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11095-006-9180-5/MediaObjects/11095_2006_9180_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11095-006-9180-5/MediaObjects/11095_2006_9180_Fig3_HTML.gif
      isPartOf:
         name:Pharmaceutical Research
         issn:
            1573-904X
            0724-8741
         volumeNumber:24
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Weijun Li
            affiliation:
                  name:University of California at San Francisco
                  address:
                     name:Departments of Biopharmaceutical Sciences and Pharmaceutical Chemistry, School of Pharmacy, University of California at San Francisco, San Francisco, USA
                     type:PostalAddress
                  type:Organization
                  name:Bayer Pharmaceuticals Corporation
                  address:
                     name:Bayer Pharmaceuticals Corporation, Berkeley, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Francis C. Szoka
            affiliation:
                  name:University of California at San Francisco
                  address:
                     name:Departments of Biopharmaceutical Sciences and Pharmaceutical Chemistry, School of Pharmacy, University of California at San Francisco, San Francisco, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Pharmaceutical Research
      issn:
         1573-904X
         0724-8741
      volumeNumber:24
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of California at San Francisco
      address:
         name:Departments of Biopharmaceutical Sciences and Pharmaceutical Chemistry, School of Pharmacy, University of California at San Francisco, San Francisco, USA
         type:PostalAddress
      name:Bayer Pharmaceuticals Corporation
      address:
         name:Bayer Pharmaceuticals Corporation, Berkeley, USA
         type:PostalAddress
      name:University of California at San Francisco
      address:
         name:Departments of Biopharmaceutical Sciences and Pharmaceutical Chemistry, School of Pharmacy, University of California at San Francisco, San Francisco, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Weijun Li
      affiliation:
            name:University of California at San Francisco
            address:
               name:Departments of Biopharmaceutical Sciences and Pharmaceutical Chemistry, School of Pharmacy, University of California at San Francisco, San Francisco, USA
               type:PostalAddress
            type:Organization
            name:Bayer Pharmaceuticals Corporation
            address:
               name:Bayer Pharmaceuticals Corporation, Berkeley, USA
               type:PostalAddress
            type:Organization
      name:Francis C. Szoka
      affiliation:
            name:University of California at San Francisco
            address:
               name:Departments of Biopharmaceutical Sciences and Pharmaceutical Chemistry, School of Pharmacy, University of California at San Francisco, San Francisco, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Departments of Biopharmaceutical Sciences and Pharmaceutical Chemistry, School of Pharmacy, University of California at San Francisco, San Francisco, USA
      name:Bayer Pharmaceuticals Corporation, Berkeley, USA
      name:Departments of Biopharmaceutical Sciences and Pharmaceutical Chemistry, School of Pharmacy, University of California at San Francisco, San Francisco, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(245)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Particles.js
Prism.js

CDN Services {📦}

Crossref

4.39s.

LINK . SPRINGER . COM {}